Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

14.73 +1.49 (+11.25%)
Streaming Delayed Price Updated: 11:14 AM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.  - URGN
From Pomerantz LLP
Via GlobeNewswire
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors
From Kirby McInerney LLP
Via Business Wire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.
From Robbins LLP
Via GlobeNewswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)
From Bleichmar Fonti & Auld LLP
Via Business Wire
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
From Faruqi & Faruqi, LLP
Via Business Wire
Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
URGN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against UroGen Pharma Ltd.
From The Law Offices of Frank R. Cruz
Via Business Wire
URGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of UroGen Pharma Ltd. Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
From Pomerantz LLP
Via GlobeNewswire
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102. 
Via Benzinga
Exposures Product Safety
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
Via NewMediaWire
Exposures Product Safety
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
Via TheNewswire.com
Exposures Product Safety
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.  - URGN
From Pomerantz LLP
Via GlobeNewswire
This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
What's Going On With UroGen Pharma Stock Wednesday?
UroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution. 
Via Benzinga
UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled
The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13. 
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.